Long COVIDNCT05812209
Stellate Ganglion Block to Treat Long COVID 19 Case Series
An observational study of Long COVID and Long Covid19, run by Metamorphosis LTD at 1 site in United States.
Trial summary
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Long COVID, Long Covid19, Post-COVID-19 Syndrome
- What is being tested?
- Stellate Ganglion Block
- Type of treatment
- Surgery or procedure
- How many people
- 41 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2022to 31 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study included 18 male and 23 females with an age range between 18 and 89 who underwent stellate ganglion block (SGB) for long COVID-19 Syndrome.
Who may be able to join
None listed.
Who cannot join
- Stellate Ganglion Block Contraindications
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
Read the detailed description
We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.
- Conditions
- Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia
- Being tested
- Stellate Ganglion Block
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Autonomic Nervous System Diseases, Anosmia, Dysgeusia, Mental Fatigue, Myalgia, Dyspnea, Dizziness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stellate Ganglion BlockProcedure or surgery
Also called SGB
Ultrasound guided block of the Stellate Ganglion with local anesthetics.
| Study group | Role | What they receive |
|---|---|---|
| SGB Patients for Long COVID 19 | Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics. Receives: Procedure: Stellate Ganglion Block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptom Response
Evaluation of the symptoms response to the Stellate Ganglion Block
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2023
- Study start1 Sep 2022
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- Metamorphosis LTD
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lisa Pearson, Metamorphosis LTD
- Investigators
- Lisa Pearson, DNAP, Principal investigator, Metamorphosis LTD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05812209
- Sponsor's protocol ID
- SGBCOVID
- Status last verified
- Apr 2023
- First submitted
- 10 Apr 2023
- Last updated
- 13 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Plan to share data file
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT05812209
- Acronym / sponsor ID
- SGBCOVID
- Conditions
- Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- Metamorphosis LTDUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 13 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
Detailed description
We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SGB Patients for Long COVID 19 | – | Procedure: Stellate Ganglion BlockPatients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study included 18 male and 23 females with an age range between 18 and 89 who underwent stellate ganglion block (SGB) for long COVID-19 Syndrome.
Key inclusion criteria (0 listed)
Key exclusion criteria (2 listed)
- Stellate Ganglion Block Contraindications
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stellate Ganglion BlockAlso: SGBUltrasound guided block of the Stellate Ganglion with local anesthetics. | Procedure or surgery | SGB Patients for Long COVID 19 |
Primary outcome
Symptom Response
Time frame: 3 months
Evaluation of the symptoms response to the Stellate Ganglion Block
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2023.
- Individual participant dataSharing planned: Yes. Plan to share data file
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lisa Pearson, DNAP principal investigator
Metamorphosis LTD
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Long COVID and Long Covid19, run by Metamorphosis LTD at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptom Response (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2023.